The Retinal Degeneration Fund announced the launch of Opus Genetics, which will aim to develop gene therapy treatments for orphan inherited retinal diseases, according to a press release.
Opus Genetics is the first spin-out company launched by the foundation, which provided $19 million in seed financing along with participation from the Manning Family Foundation and Bios Partners. The funding will allow the company to advance the preclinical research of its scientific founders, Jean Bennett, MD, PhD, Junwei Sun, and Eric Pierce, MD, PhD, the release said.
“I’ve dedicated my career